LBT Innovations Limited Signs Significant Contract with AstraZeneca AB

Australian medical technology company LBT Innovations Limited (ASX: LBT) has secured a significant agreement with AstraZeneca AB for the sale of five APAS® Independence instruments. The contract, valued between AU$3.4 million and AU$4.1 million, includes annual maintenance and support services over seven years. The installation of these instruments is scheduled over the next six months.

This deal, stemming from positive validation studies, highlights the commercial traction LBT Innovations is gaining within the pharmaceutical sector. The initial rollout of APAS® Independence instruments indicates potential for further orders and broader adoption by large pharmaceutical companies, demonstrating the technology's capability and reliability for environmental monitoring during drug manufacturing.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com